Skip to main
BSX

Boston Scientific (BSX) Stock Forecast & Price Target

Boston Scientific (BSX) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 47%
Buy 53%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Boston Scientific demonstrates a robust growth trajectory, evidenced by impressive sales increases across multiple product lines, including a 35% year-over-year growth in Watchman sales and a 63% increase in electrophysiology (EP) sales due to market share gains. The company's guidance for Q4 indicates organic sales growth of 11-13% year-over-year, alongside anticipated GAAP EPS between $0.48 and $0.52, reflecting strong financial health and operational efficiency. Additionally, promising indicators such as expected sales exceeding $60 million for Nalu in 2025, with a targeted growth rate surpassing 25% in 2026, underscore a positive long-term outlook for Boston Scientific's market position and revenue potential.

Bears say

Boston Scientific faces a challenging financial outlook driven by several key factors, including anticipated foreign exchange headwinds projected at approximately $0.04 per share, which complicates revenue growth expectations. The company's reliance on its Cardiac Rhythm Management (CRM) and Drug-Eluting Stents (DES) portfolios, which operate in mature markets experiencing persistent pricing pressure, raises concerns regarding sustainable growth and profitability. Additionally, setbacks in product launches and integration of acquisitions may hinder the firm's ability to meet both internal targets and consensus expectations, further undermining future growth prospects.

Boston Scientific (BSX) has been analyzed by 17 analysts, with a consensus rating of Buy. 47% of analysts recommend a Strong Buy, 53% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Boston Scientific and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Boston Scientific (BSX) Forecast

Analysts have given Boston Scientific (BSX) a Buy based on their latest research and market trends.

According to 17 analysts, Boston Scientific (BSX) has a Buy consensus rating as of Jan 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $124.41, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $124.41, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Boston Scientific (BSX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.